Indoco Remedies Limited

NSE:INDOCO.NS

307.9 (INR) • At close November 8, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12014 Q12013 Q12012 Q42012 Q3
Revenue 4,306.64,314.94,496.44,587.54,735.84,168.14,287.44,111.54,049.53,952.14,005.1743,488.73,729.23,814.32,950.9783,336.63,230.52,6682,631.3542,834.52,862.12,471.82,449.9112,480.72,362.62,127.61,986.31,539.71,648.4871,502.6
Cost of Revenue 1,3682,662.72,554.11,423.21,473.11,286.81,314.61,303.51,273.91,3211,384.4561,086.81,063.21,103.1934.61943.5902.1816.2770.599828.1895.9856.1844.992882.2796.1712.9725.7596.9948.526634.8
Gross Profit 2,938.61,652.21,942.33,164.33,262.72,881.32,972.82,8082,775.62,631.12,620.7182,401.92,6662,711.22,016.3682,393.12,328.41,851.81,860.7552,006.41,966.21,615.71,604.9191,598.51,566.51,414.71,260.6942.8699.961867.8
Gross Profit Ratio 0.6820.3830.4320.690.6890.6910.6930.6830.6850.6660.6540.6880.7150.7110.6830.7170.7210.6940.7070.7080.6870.6540.6550.6440.6630.6650.6350.6120.4250.578
Reseach & Development Expenses 152.7246.9233.4241.7257.7198.8240.7198.3187.8182.5196.719171.1213.3165.3164.236173.6156.6102.6140.32129.1116.4111.2131.155124.4127.5132.142.927.477.70832.6
General & Administrative Expenses 000000596.036000583.53000767.013000712.438000584.0870000049.4820
Selling & Marketing Expenses 000000715.664000458.47000435.486000521.48000399.3400000646.890
SG&A 1,474.61,202.81,482.51,400.61,451.61,212.31,311.71,048.51,186.11,037.51,042874.5986.1980.31,202.499728.7751.5658.31,233.918682.3641.4609.1983.427591.1583.1563.4001,341.152255.5
Other Expenses 2,671.610.326.623.544.32,269.62,261.52,1611,865.81,935.12,094.2781.610.18.6-5.1533.65.22.6-8.4977.25.86.422.8855.63.43940.5743.300
Operating Expenses 2,824.31,449.71,715.92,778.82,763.12,468.42,502.22,359.32,053.62,117.62,290.9971,859.61,996.12,064.51,591.5131,960.11,906.91,556.61,750.8691,833.61,820.31,561.41,670.4431,528.51,621.61,467.9983.4770.7643.976728.4
Operating Income 114.3202.5226.4409543.9417475.6452.3725.5524.8651.091543.9669.9646.7424.855433421.5295.2109.886172.8145.954.3-65.52470-55.1-53.2277.2172.1200.779135.2
Operating Income Ratio 0.0270.0470.050.0890.1150.10.1110.110.1790.1330.1630.1560.180.170.1440.130.130.1110.0420.0610.0510.022-0.0270.028-0.023-0.0250.140.1120.1220.09
Total Other Income Expenses Net -162.7-132.8103.4-182.7-81.1-77.9-86.4-70.1-52.5-41.3-53.579-38.1-20.4-33.8-89.284-56.7-53.7-54.9-32.363-62.1-47.9-54.9157.902-31.7-46.7-68.7-27.3-62.2-56.378-45.5
Income Before Tax -48.469.7329.8226.3462.8339.1389.2382.2673483.5597.512505.8649.5612.9335.571376.3367.8240.377.523110.798-0.692.37838.3-101.8-121.9249.9109.9144.40189.7
Income Before Tax Ratio -0.0110.0160.0730.0490.0980.0810.0910.0930.1660.1220.1490.1450.1740.1610.1140.1130.1140.090.0290.0390.034-00.0380.015-0.043-0.0570.1260.0710.0880.06
Income Tax Expense 51.751.5109.570.7110.497.3131.2100.7175.797.8193.017175.9232.6216.385.616122.7111.369.923.94919.719.9-19-22.382-14.4-27.33.149.518.114.8915.9
Net Income -95.726.2227163350.8243.9258.1281.5497.3385.7404.495329.9416.9396.6249.955253.6256.5170.453.5749178.118.5114.7652.7-74.5-121.9200.491.8129.08573.8
Net Income Ratio -0.0220.0060.050.0360.0740.0590.060.0680.1230.0980.1010.0950.1120.1040.0850.0760.0790.0640.020.0320.0270.0070.0470.021-0.032-0.0570.1010.060.0780.049
EPS -1.040.282.391.773.812.652.83.055.44.194.393.584.524.32.712.752.781.850.580.990.850.21.240.57-0.81-1.322.1711.410.8
EPS Diluted -1.040.282.391.773.812.652.83.055.44.194.393.584.524.32.712.752.781.850.580.990.850.21.240.57-0.81-1.322.1711.410.8
EBITDA 418.1477.7488.7652.5758655.8652.5624882725.8814.08736.1874.5877.6554.735605.4612.4489.1269.63355.9332.1230.5327.586252.8124.7117.2371.9245.4246.676183.321
EBITDA Ratio 0.0970.1110.1090.1420.160.1570.1520.1520.2180.1840.2030.2110.2350.230.1880.1810.190.1830.1020.1260.1160.0930.1340.1020.0530.0550.1870.1590.150.122